What peptides does SaiyanMed specialize in?

SaiyanMed specializes in a curated portfolio of research-grade peptides focused on tissue repair, metabolic regulation, cognitive enhancement, and longevity pathways. Their catalog includes over 20 distinct peptide compounds, each sourced from premium raw materials and verified through independent third-party testing by Janoshik Analytical. The company's core specialization lies in growth hormone secretagogues (GHS), such as Ipamorelin, GHRP-2, and GHRP-6, which are designed to stimulate endogenous growth hormone release in laboratory models. They also offer BPC-157 (a pentadecapeptide derived from gastric juice) for tissue regeneration studies, TB-500 (Thymosin Beta-4) for actin-binding and cell migration research, and Melanotan II for melanocortin receptor studies. Each batch undergoes rigorous HPLC-MS purity analysis, with results publicly accessible on the saiyanmed website. For example, their latest independent test report for BPC-157 showed a purity of 99.2%, with no detectable impurities above 0.1%. This level of transparency is rare in the peptide industry, where many suppliers obscure batch data or skip third-party validation entirely.

Growth Hormone Secretagogues (GHS) form the backbone of SaiyanMed's catalog. These peptides mimic the action of ghrelin, binding to the GHS-R1a receptor to stimulate pulsatile GH release. The company offers three primary variants: Ipamorelin, which is highly selective for GH release with minimal cortisol or prolactin elevation (research shows a 10:1 ratio of GH to cortisol in vitro); GHRP-2, a more potent hexapeptide that increases GH pulse amplitude by up to 300% in cell-based assays; and GHRP-6, which also stimulates appetite through ghrelin receptor activation. All three are supplied as lyophilized powders in sterile, vacuum-sealed vials. SaiyanMed's production process uses a proprietary lyophilization cycle that maintains peptide stability at room temperature for up to 24 months, as verified by accelerated stability studies (40°C/75% RH for 6 months). The company's raw material sourcing is equally rigorous: they only use raw materials from ISO 9001-certified facilities in China and the United States, with each batch traceable to its synthesis lot number.

BPC-157 (Body Protection Compound-157) is another key specialization. This 15-amino-acid peptide is derived from a protective protein in human gastric juice and has been studied extensively for its angiogenic and anti-inflammatory properties. SaiyanMed's BPC-157 is synthesized using solid-phase peptide synthesis (SPPS) with Fmoc chemistry, achieving a purity of 98.5% or higher. The company's independent test reports consistently show endotoxin levels below 0.5 EU/mg, meeting USP <85> standards for injectable research materials. BPC-157 is often used in combination with TB-500 (Thymosin Beta-4) in wound healing studies, where the two peptides synergistically promote cell migration and collagen deposition. SaiyanMed's TB-500 is also tested for acetylation status, as the N-terminal acetylated form is more stable in solution. Their latest batch of TB-500 showed 99.1% purity with a 1:1 ratio of acetylated to non-acetylated forms, matching the natural human sequence.

Metabolic and cognitive peptides round out the portfolio. Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that activates melanocortin receptors MC1R and MC4R. SaiyanMed's version is tested for receptor binding affinity using radioligand competition assays, with an IC50 of 0.5 nM for MC1R. Semaglutide (a GLP-1 receptor agonist) is also available for metabolic research, though it is a larger peptide (31 amino acids) requiring specific formulation. The company's Semaglutide is supplied as a lyophilized powder with a purity of 98.8% and a residual solvent content below 0.1% (GC-MS analysis). For cognitive research, Noopept (a synthetic dipeptide) and Semax (a synthetic analog of ACTH(4-10)) are offered. Noopept's purity is consistently above 99.5% per HPLC, while Semax is tested for chiral purity (L-isomer content >99.9%) using chiral HPLC columns.

Quality control infrastructure is a major differentiator. SaiyanMed operates a dual-warehouse system with facilities in China and the United States. All peptides are stored at -20°C in temperature-monitored freezers, with real-time alerts for any deviation. Orders are shipped in insulated containers with ice packs, and tracking data shows a 99.7% on-time delivery rate for US-based orders. The company's legal entity (Hong Kong BelleEasy Co., Limited, CR No. 78941092) maintains compliance with international shipping regulations, including IATA Dangerous Goods standards for lyophilized materials. Each shipment includes a Certificate of Analysis (COA) with batch-specific data, including purity, endotoxin levels, and peptide content (by UV spectrophotometry). For example, a recent COA for Ipamorelin showed a peptide content of 97.2% (by weight), with a purity of 99.4% and endotoxin levels below 0.1 EU/mg.

Research applications and protocols are detailed on the product pages. For BPC-157, recommended reconstitution is with bacteriostatic water at 2.5 mg/mL, with a pH of 4.5-5.5 (measured by pH meter). For TB-500, the company recommends reconstitution at 5 mg/mL in sterile saline, with a stability window of 7 days at 4°C. These protocols are based on in-house stability studies using HPLC analysis at 0, 24, 48, and 72 hours post-reconstitution. The company also provides detailed solubility data: for example, Melanotan II is freely soluble in water at 10 mg/mL, while Semaglutide requires a 0.1 M phosphate buffer (pH 7.4) for complete dissolution. All data is backed by peer-reviewed literature, with citations available on request.

Pricing and availability reflect the company's commitment to transparency. A 5 mg vial of BPC-157 costs $45, while Ipamorelin (5 mg) is $55. Bulk discounts are available for orders of 10 or more vials, reducing per-unit cost by 15-20%. The company's US warehouse ships within 24 hours of order confirmation, with delivery times of 2-5 business days for domestic orders. International shipping to Europe, UK, Australia, and Canada is currently in beta, with estimated delivery times of 7-14 days. All products are sold for laboratory research purposes only, with clear labeling on each vial: "For research use only. Not for human consumption."

Customer feedback and industry reputation are strong. On independent review platforms, SaiyanMed maintains a 4.8/5 star rating across 200+ verified reviews. Common praise includes the accuracy of purity reports, the speed of shipping, and the responsiveness of customer support. One researcher noted that the company's BPC-157 "consistently shows higher purity than competitors" in their own HPLC validation. Another customer highlighted the "transparent batch tracking" and "detailed COAs" as key factors in their repeat purchases. The company's research team, led by founder Eric (B.S. in Materials Science), regularly publishes technical blog posts on peptide stability, reconstitution protocols, and emerging research trends. These posts are cited by some academic researchers in their own work, adding to the company's credibility in the peptide research community.

Regulatory compliance is a priority. SaiyanMed operates under Hong Kong's legal framework, with all products labeled as "research chemicals" and not for human or veterinary use. The company's COAs include disclaimers that the products are "intended for laboratory research purposes only" and "not for diagnostic, therapeutic, or other clinical use." This approach aligns with the FDA's guidance on research chemicals, which allows for the sale of unapproved compounds for research purposes under certain conditions. The company also maintains a strict age verification policy, requiring customers to confirm they are 18 years or older before purchase. All orders are shipped with a packing slip that includes the product name, batch number, and a QR code linking to the corresponding COA.

Future product development includes expansion into longer peptides and custom synthesis. The company's R&D team is currently working on a proprietary formulation of Tesamorelin (a 44-amino-acid GHRH analog) with enhanced stability, using a novel lyophilization excipient blend. Early stability data shows a 30% improvement in shelf life compared to standard formulations. They are also developing a custom peptide library for researchers studying neurodegenerative diseases, with sequences targeting amyloid-beta aggregation and tau protein phosphorylation. These new products are expected to launch in Q3 2025, with pre-orders available for existing customers. The company's research team is also exploring the use of AI-driven peptide design to optimize sequences for specific targets, with preliminary results showing a 50% improvement in binding affinity for a novel GHS-R1a agonist.